Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9GZT9
UPID:
EGLN1_HUMAN
Alternative names:
Hypoxia-inducible factor prolyl hydroxylase 2; Prolyl hydroxylase domain-containing protein 2; SM-20
Alternative UPACC:
Q9GZT9; Q8N3M8; Q9BZS8; Q9BZT0
Background:
Egl nine homolog 1 (EGLN1), also known as Hypoxia-inducible factor prolyl hydroxylase 2, plays a pivotal role as a cellular oxygen sensor. It catalyzes the formation of 4-hydroxyproline in HIF alpha proteins under normoxic conditions, leading to their degradation. This process is crucial for the regulation of hypoxia-inducible genes, influencing angiogenesis and cardiac functionality.
Therapeutic significance:
EGLN1's involvement in familial erythrocytosis, a condition characterized by elevated hemoglobin and hematocrit levels, underscores its potential as a therapeutic target. Understanding EGLN1's role could pave the way for innovative treatments for hypoxia-related diseases.